Unknown

Dataset Information

0

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.


ABSTRACT: BACKGROUND:We evaluated pretreatment total lymphocyte count (TLC, marker of immunosuppression), neutrophil-to-lymphocyte ratio (NLR, marker of inflammation), and overall survival (OS) in patients with extensive-stage small-cell lung cancer (ES-SCLC). METHODS:Pretreatment blood characteristics, age, sex, performance status, race, stage (M1a vs. M1b), number and location of metastases, weight loss, smoking status, chemotherapy cycles (<4 vs. ?4), thoracic radiotherapy dose (<45 vs. ?45?Gy), and receipt of prophylactic cranial irradiation (PCI) were evaluated in 252 patients with ES-SCLC treated in 1998-2015. Factors significant in univariate analysis were selected as covariates for a multivariate Cox model. RESULTS:Pretreatment TLC was below normal (<1.0?×?103/µL) in 58 patients (23%). Median OS time was 11.0?months and was worse for those with TLC???1.5?×?103/µL (9.8 vs. 12.0?months) and pretreatment NLR?>?4.0 (9.4 vs. 13.9?months). Multivariate analysis identified low TLC (hazard ratio [HR] 0.734, 95% confidence interval [CI] 0.565-0.955, P?=?0.021) and high NLR (HR 1.521, 95% CI 1.172-1.976, P?=?0.002) as predicting inferior survival. Age (>63?y), sex (male), performance status (?2), chemotherapy cycles (<4), radiation dose (<45?Gy), and no PCI also predicted worse OS (P?

SUBMITTER: Suzuki R 

PROVIDER: S-EPMC5856620 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.

Suzuki Ryoko R   Lin Steven H SH   Wei Xiong X   Allen Pamela K PK   Welsh James W JW   Byers Lauren A LA   Komaki Ritsuko R  

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20180202 3


<h4>Background</h4>We evaluated pretreatment total lymphocyte count (TLC, marker of immunosuppression), neutrophil-to-lymphocyte ratio (NLR, marker of inflammation), and overall survival (OS) in patients with extensive-stage small-cell lung cancer (ES-SCLC).<h4>Methods</h4>Pretreatment blood characteristics, age, sex, performance status, race, stage (M1a vs. M1b), number and location of metastases, weight loss, smoking status, chemotherapy cycles (<4 vs. ≥4), thoracic radiotherapy dose (<45 vs.  ...[more]

Similar Datasets

| S-EPMC7317009 | biostudies-literature
| S-EPMC8075197 | biostudies-literature
| S-EPMC4616560 | biostudies-other
| S-EPMC6543004 | biostudies-literature
| S-EPMC7120218 | biostudies-literature
| S-EPMC7732694 | biostudies-literature
| S-EPMC9801394 | biostudies-literature
| S-EPMC4783753 | biostudies-other
| S-EPMC5690700 | biostudies-literature
| S-EPMC5784637 | biostudies-literature